Comparison of the efficacy of reteplase and urokinase intravenous thrombolysis in treatment of patients with acute ST segment elevation myocardial infarction
10.3760/cma.j.issn.1008-6706.2016.14.021
- VernacularTitle:瑞替普酶与尿激酶在急性 ST 段抬高型心肌梗死静脉溶栓治疗中的疗效比较
- Author:
Qiaoling YUAN
- Publication Type:Journal Article
- Keywords:
Reteplase;
Urokinase;
Myocardial infarction;
Thrombolytic
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(14):2158-2161
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the curative effect of reteplase and urokinase in treatment of acute ST elevation myocardial infarction.Methods 116 patients with acute ST segment elevation myocardial infarction who were diagnosed and received treatment in our hospital from October 2013 to October 2015,were selected as the study subjects and were randomly divided into two groups with 58 cases in each group according to the single blind method. The control group was treated with urokinase thrombolytic therapy,while the patients in the observation group were treated with reteplase thrombolytic therapy.The thrombolytic recanalization rate,and adverse event incidence were compared in the two groups.Results The clinical judgement thrombosis recanalization rates in the observation group after 0.5h,1h,1.5h,2h of thrombolysis were 27.59%,60.34%,81.03% and 86.21% respectively,which were sig-nificantly higher than 15.52%,29.31%,62.07%,70.69% of the control group,the differences between the two groups were statistically significant(χ2 =3.853,3.907,3.898,3.524,all P <0.05).After 1.5 h of thrombolytic ther-apy,the results of underwent coronary angiography showed that the infarct related artery recanalization rate of the observation group was 70.69%.The complete recanalization rate was 60.34%,which was significantly higher than 55.17% and 41.37% in control group,the differences between the two groups were statistically significant(χ2 =4.032,4.153,all P <0.05).There was no significant difference between the two groups in the incidence of adverse events(χ2 =0.250,P >0.05).Conclusion Reteplase for acute ST segment elevation myocardial infarction thrombo-lytic therapy is better than urokinase,has a high patency rate and low incidence of adverse events,it is safe and worthy of clinical popularization and application.
